
The assessment of a compound’s potential DNA reactivity (mutagenicity) is a critical component of its safety evaluation. The biological activity of a compound is generally understood to be closely associated with its chemical structure. Because computer-aided quantitative structure-activity relationship (QSAR) models can provide high-throughput and rapid evaluation of compounds, the development of robust computational prediction models has substantial practical value. Herein, we developed the Decrypt Substance Toxicity (DSTOX) Mutagen Profiler software through a multi-strategy fusion approach. By integrating statistical rule-based models, expert knowledge rule-based models, analogue search, carcinogenicity data search, and International Council for Harmonisation (ICH) classification determination, the software generates mutagenicity assessment classification reports adhering to ICH M7 guidelines. Internal validation of the DSTOX statistical model indicated an accuracy of 92.0%. When combined with expert knowledge rule-based models and analogue cross-referencing, the DSTOX model exhibited robust mutagenicity prediction performance. External validation achieved an accuracy of 84.0% and a sensitivity (recall) of 82.8% for mutagenic compounds. The model’s performance metrics were generally comparable to those of current internationally recognized mainstream prediction tools.
Chronic renal failure (CRF) is a progressive disease characterized by a sustained loss of kidney function, for which current therapies remain insufficient. Growing evidence closely links the CRF pathogenesis to renal aging; therefore, targeting aging processes might have therapeutic promise. Herein, we implemented a novel strategy to identify potential anti-CRF agents from anti-aging Chinese herbal medicines. Phenotypic screening indicated that the 75% ethanol extract of Stellaria yunnanensis Franch (JM11002) exhibited marked anti-aging activity, by prolonging the lifespan of Caenorhabditis elegans and decreasing the proportion of SA-β-gal-positive senescent MRC-5 cells. Importantly, JM11002 also ameliorated renal dysfunction, inflammation, and fibrosis in both unilateral ischemia-reperfusion injury (UIRI) and unilateral ureteral obstruction (UUO) mouse models. Phytochemical investigation identified 20-hydroxyecdysone (JM11201), a major active component of JM11002 , which recapitulated the renoprotective effects in both the UUO model and unilateral ischemia-reperfusion injury with contralateral nephrectomy (UIRIx) model. Mechanistically, 20-hydroxyecdysone suppressed the TGF-β1/Smad3 signaling pathway and decreased the expression of fibrosis-related proteins in UUO kidneys. In summary, through an aging-intervention strategy, we discovered the renoprotective effect of Stellaria yunnanensis Franch extract and its active component, 20-hydroxyecdysone, two promising candidates for the development of novel CRF therapies.
Vicatia thibetica de Boiss (V. thibetica), a traditional medicinal and edible plant used by the Bai ethnic group in China, is known for its effects in tonifying qi, nourishing the blood, dispelling dampness, and relieving itching. Previous studies have shown that its root extract (JM02001) exerts anti-aging effects by promoting collagen expression and antioxidant potential. However, its anti-skin aging efficacy in vivo and its bioactive constituents have been largely unexplored. Herein, JM02001 was found to mitigate extracellular matrix (ECM) loss, restore superoxide dismutase-1 (SOD-1) expression, suppress matrix metalloproteinase-9 (MMP-9) expression, and increased the epidermal barrier intensity in D-galactose-treated mice. The ethyl acetate fraction (JM02102) exhibited the most promising anti-glycation, antioxidant, and collagen-promoting activities. Chlorogenic acid (CGA) was identified as an important active compound. Both JM02102 and CGA alleviated ECM degradation and enhanced epidermal barrier function in D-galactose-treated mice. Furthermore, in glucocorticoid-treated mice, they restored dermal and epidermal thickness, suppressed REDD1 and p16 INK4A expression, and enhanced epidermal barrier function. Therefore, our findings indicated that the extract of V. thibetica root and its compound CGA protect against skin aging by preserving ECM, decreasing oxidative stress, and reinforcing the skin barrier, thus validating its traditional use and highlighting its potential as a source of anti-aging therapeutics.
Traditional Chinese medicine has shown therapeutic potential in treating osteoarthritis (OA) by regulating inflammation and maintaining cartilage homeostasis. However, the complex compositions of herbal medicines and the lack of efficient screening strategies have hindered the identification of active compounds and their molecular mechanisms. To address these challenges, this study used graph neural networks (GNNs) for drug discovery and demonstrated their potential in elucidating therapeutic mechanisms. Using an in-house GNN model, we identified Paederia scandens as a promising candidate for OA treatment. Experimental validation confirmed that Paederia scandens improved cartilage metabolic homeostasis and mitigated subchondral bone sclerosis. Further analysis implicated asperuloside, a major constituent of Paederia scandens , as a key bioactive compound contributing to these therapeutic effects. Transcriptomic profiling and protein-protein interaction network analysis identified Integrin Subunit Beta 1 as a potential central regulatory hub. Asperuloside treatment was found to reshape cartilage gene expression; downregulate cytokine and chemokine signaling pathways; and alleviate inflammation, while enhancing cartilage matrix synthesis and decreasing matrix degradation. Further in vivo and in vitro experiments consistently supported these findings. Collectively, our findings indicated that asperuloside is a promising OA therapeutic candidate. Moreover, the GNN-driven framework established in this study provides a novel strategy for modernizing traditional Chinese medicine and accelerating the discovery of bioactive compounds. This work highlights the critical role of GNNs in integrating computational prediction with biological validation to facilitate mechanistic exploration and advance precision drug development for complex diseases such as OA.
Accurate repair of DNA double-strand breaks (DSBs) is essential for maintaining genomic integrity. RAD51, the core recombinase in homologous recombination, plays central roles in repairing DNA damage and protecting stalled replication forks. In normal cells, RAD51 helps maintain genomic integrity; however, in cancer, its overexpression often supports replication-stress tolerance, as well as resistance to chemotherapy, radiotherapy, and PARP inhibitors. RAD51 is tightly controlled at multiple levels, including transcriptional, post-transcriptional, and post-translational regulation, which together shape its activity in different biological contexts. This review summarizes the structural features of RAD51, its regulatory networks, and its roles in human disease, with particular emphasis on cancer progression and treatment resistance. Currently available RAD51 inhibitors, their mechanisms of action, and the main challenges that still limit clinical translation are discussed. Together, current findings indicate that RAD51 is a key genome maintenance factor and a promising therapeutic target in precision oncology.